An analysis of past research conducted by the Salt Lake City-based University of Utah Health John A. Moran Eye Center found cause for further testing to determine if cataracts might someday be ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The phase 3 OPTIMIZE trial met both primary efficacy ...
Credit: Getty Images. OCS-01 is a novel, high concentration (15mg/mL), topical formulation of dexamethasone. Once-daily administration of an investigational corticosteroid eye drop (OCS-01) was found ...
Please provide your email address to receive an email when new articles are posted on . A novel preservative-free betamethasone eye drop formulation showed efficacy in preventing inflammation and pain ...
OPTIMIZE (Once-daily Post-ocular surgery Treatment for InflaMmation and paIn to minimiZE drops) is a double-blind, placebo-controlled Phase 3 trial conducted in 25 sites across the US with 241 ...
FDA approvals in 2025 introduced novel therapies and devices across ophthalmic subspecialties, emphasizing sustained efficacy ...
TEL AVIV - PainReform Ltd. (NASDAQ:PRFX) has initiated its development plan for OcuRing-K, a sustained-release ocular therapy designed to deliver ketorolac following cataract surgery, according to a ...
A study by LV Prasad Eye Institute highlights rising antimicrobial resistance in post-cataract infections, with aggressive ...
A small proof-of-concept study of robotic-assisted cataract surgery reports successful outcomes with no treatment-related ...
According to a meta-analysis, tear film stability shows deterioration after cataract surgery, with symptoms potentially lasting up to 3 months postoperatively. However, the effect of cataract surgery ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback